title: Palliative chemotherapy in head and neck squamous cell cancer - What is best in Indian population? A time without symptoms, treatment toxicity score based study.
abstract: BACKGROUND
  Patients with recurrent and metastatic head and neck Squamous Cell Cancer (HNSCC) have poor prognosis with limited treatment options. In view of decimal prognosis, the treatment decision should include quality of life (QOL) issues, cost-effectiveness besides the response rates and survival.
  
  
  OBJECTIVE
  Present retrospective analysis was conducted to evaluate efficacy (disease-free survival), pharmacoeconomics, and toxicity profile of four (4) different regimens, viz. gefitinib alone, gefitinib with methotrexate, methotrexate alone, or 5-FU with cisplatin.
  
  
  METHODS
  Case records between 2007 September and 2008 September were analyzed, 68 patients were found suitable for analysis. Patients received gefitinib (250 mg/day), methotrexate as 50 mg intramuscular weekly or a combination of the same or 5-FU 750 mg/m(2)/day for 4 days along with cisplatin 75 mg/m(2)/day on day 1 in 21-day cycle.
  
  
  RESULTS
  A total of 68 patients received therapy. Fifty-one patients have clinically meaningful response (stable disease + complete + partial responses) (75%) and had symptomatic improvement. The median progression-free survival was significantly superior in responders (those who achieved partial or complete response) (8.4 months vs. 3.1 months, P=0.001). Methotrexate with gefitinib had maximum median survival and better overall QOL compared to the other treatment regimens. Weekly methotrexate is relatively cost-effective followed by methotrexate with gefitinib and gefitinib alone. 5-FU with cisplatin in our experience does not appear so attractive in view of high complication rates (when given in full doses) and prolonged hospital stay.
  
  
  CONCLUSIONS
  Based on the results of this retrospective analysis, methotrexate weekly as single agent or in combination with gefitinib appears as an attractive alternative regimen for patients with metastatic HNSCC including those having poor performance status. A prospective study was planned and submitted to the local ethics committee based on above results to validate these results and compare methotrexate and gefitinib arm with 5-FU + cisplatin.
authors.affiliation: Department of Pathology, Osmania Medical College, Hyderabad, Andhra Pradesh, India.
authors.forename: V
authors.initials: V
authors.lastname: Anuradha
authors.forename: B B
authors.initials: BB
authors.lastname: Anand
authors.forename: A V S
authors.initials: AV
authors.lastname: Suresh
authors.forename: Sudha
authors.initials: S
authors.lastname: Sinha
authors.forename: S Chinna
authors.initials: SC
authors.lastname: Babu
authors.forename: K
authors.initials: K
authors.lastname: Suresh
keywords: Head and neck cancer; India; quality of life; time without symptoms treatment toxicity